Screener
Pacific Biosciences of California PACB Settlement charges
Settlement charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept pacb:SettlementCharges.
The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001299130-26-000122
| (In thousands, except per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 23,022 | 22,529 | 42,630 | 51,582 |
| Sales, general and administrative | 33,393 | 36,175 | 64,546 | 76,343 |
| Impairment charges | — | — | — | 15,000 |
| Settlement charges | — | — | 15,400 | — |
| Gain on disposal of assets | — | — | (45,796) | — |
| Amortization of acquired intangible assets | 833 | 833 | 1,666 | 362,875 |
| Change in fair value of contingent consideration | — | — | — | (18,700) |
| Total operating expense | 57,248 | 59,537 | 78,446 | 487,100 |
Item 1. Financial Statements (unaudited):
FAQ
- What is Pacific Biosciences of California's settlement charges?
- Pacific Biosciences of California (PACB) reported settlement charges of $0 in Q2 2026.
- What does settlement charges mean?
- Settlement charges as reported by Pacific Biosciences of California, Inc..
Ask your AI about Pacific Biosciences of California's settlement charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude